PTT Plc, a leading national oil and gas conglomerate, has announced plans to sell a portion of its shares in Taiwan-based Lotus Pharmaceutical to enhance its financial flexibility. The company will sell no more than 2% of Lotus Pharmaceutical’s shares listed on the Taiwan Stock Exchange. PTT currently owns a 37% stake in Lotus Pharmaceutical through its wholly-owned subsidiary, Innobic (Asia).
The share sale is scheduled to be completed by July 2026. Following the transaction, Innobic will retain a minimum of 36% ownership in Lotus Pharmaceutical, reaffirming its continued confidence in the company’s growth prospects.
This strategic move aims to provide PTT with greater financial leeway to support future expansion in the life sciences sector. The recent adjustment aligns with PTT’s revised focus on its life science business, adapted to changing market conditions and competitive dynamics. The goal is to enable Lotus Pharmaceutical to pursue self-funded growth and generate long-term benefits for PTT and Thailand.
An estimated pre-tax profit of approximately 6.2-7.6 billion baht from the share revaluation is expected to be recorded in the third quarter, according to securities analyst Sornchai Pitthayaprug. Despite the sale, PTT maintains control over Lotus Pharmaceutical and projects an annual profit support of around 1.8 billion baht.
Lotus Pharmaceutical, listed on the Taiwan Stock Exchange, is a distributor of medical drugs in South Korea and the US. Both Innobic and Lotus aim to develop the generic drug market in Southeast Asia to bolster regional public health. Lotus is particularly focused on treating non-communicable diseases (NCDs), a growing demand driven by aging populations across Asia, as noted by Buranin Rattanasombat, chairman of Innobic (Asia).